Preoperative tear volume may affect LASIK recovery

Article

Preoperative tear volume may affect recovery of the ocular surface after LASIK and could increase the risk for chronic dry eye.

Preoperative tear volume may affect recovery of the ocular surface after LASIK and could increase the risk for chronic dry eye, according to a study published in the January issue of Investigative Ophthalmology & Visual Science.

Keiko Konomi and colleagues from the Schepens Eye Research Institute, Boston, USA enrolled 24 patients undergoing LASIK. Tear break-up time, Schirmer testing with and without anaesthesia, rose bengal staining, central corneal sensitivity, nucleus-to-cytoplasmic ratio and globlet cell density were evaluated two weeks prior to surgery and one week, three months and nine months after surgery. Subjects were classified into two outcome groups, the non-dry eye group (NDEG) and the chronic dry eye group (CDEG), on the basis of dry eye status nine months after surgery.

All parameters, except rose bengal staining, deteriorated significantly after surgery but returned to preoperative levels within three to nine months. The CDEG group had significantly lower preoperative Schirmer test values with an without anaesthesia and were delayed in recovery after surgery in globlet cell density, rose bengal staining, Schirmer test values without anaesthesia and tear break-up time. Results of preoperative Schirmer tests without anaesthesia positively correlated with tear break-up time nine months after surgery.

The authors believe that these findings may help ophthalmologists to determine if pre-treatment is necessary before surgery or if surgery is appropriate at all.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.